Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsIpcalaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Super Six intraday picks for the day

      Kunal Saraogi of Equityrush advises buying UCO Bank with a target of Rs 43.

    • Upbeat on IPCA; buy stock on domestic growth: Nomura

      This is depite the fact that exports revival in its US and institutional businesses seems distant as the US- Food and Drug Administration (FDA) regulatory issues are likely to remain unresolved in the next two years.

    • Buy IPCA Laboratories, targets Rs 502-505: Rajat Bose

      According to Rajat Bose of rajatkbose.com, one can buy IPCA Laboratories for targets of Rs 502 and Rs 505.

    • Cipla may test Rs 491, IPCA Labs Rs 477: Rajat Bose

      Rajat Bose of rajatkbose.com is of the view that Cipla may test Rs 491 while IPCA Labs may hit Rs 477.

    • CLSA upgrades IPCA Labs but cuts EPS on flat sales guidance

      IPCA has lost 50 percent of its market cap in the past year due to the US FDA issues at three facilities and its impact on other businesses. According to the brokerage firm, India business growth has remained resilient in the turmoil.

    • Buy State Bank of India, ICICI Bank, IPCA Labs: Rajat Bose

      Rajat Bose of rajatkbose.com recommends buying ICICI Bank, State Bank of India and IPCA Laboratories.

    • Here are top 10 stocks to focus on April 26

      CNBC-TV18's analysts gives stocks to keep on your radar for trade today - stocks expected to be under pressure today are ABB India, IPCA Labs, State Bank of Travancore, Sun Pharma, ITC, Godfrey Phillips and VST Industries while the stocks expected to gain are Indiabulls Housing, Bharti Airtel, Shilcar Tech, Novartis India and Excel Crop Care.

    • Buy India Cements, Havells India: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com is of the view that one can buy India Cements and Havells India.

    • Positive on IPCA, but see 4% impact on earnings: Phillip Capital

      Surya Patra, pharma analyst at Phillip Capital now estimates IPCA's institutional revenues to fall to around Rs 200 crore, from its earlier estimate of around Rs 260 crore

    • Lower malaria opportunity in Africa, pricing policy may hit IPCA

      According to Credit Suisse, slower ramp-up in malaria tender business in Africa, pricing policy hit in India portfolio starting April 2016 and potential nine-month delay in resolution in the US post the warning letter may have combined impact of 17 percent to FY17 earnings per share (EPS) and 11 percent to FY18 EPS.

    • Prefer Ipca Laboratories, says Mayuresh Joshi

      Mayuresh Joshi of Angel Broking is of the view that one may prefer Ipca Laboratories.

    • Pick Ipca Lab, Siemens: Amit Harchekar

      Amit Harchekar of A-Plus Analytics is of the view that one may pick Ipca Laboratories and Siemens.

    • Ipca Laboratories may test Rs 900, says Mayuresh Joshi

      Mayuresh Joshi of Angel Broking feels that Ipca Laboratories may test Rs 900.

    • Buy Hindalco Industries, Marico, Ipca Labs: Rahul Mohindar

      Rahul Mohindar of viratechindia.com recommends buying Hindalco Industries, Marico and Ipca Labs.

    • Accumulate IPCA Labs on correction: Mayuresh Joshi

      Mayuresh Joshi of Angel Broking recommends accumulating IPCA Labs on correction.

    • Buy Cipla, Take Solutions, Ipca Laboratories: Kunal Bothra

      Kunal Bothra, Head of Advisory at LKP recommends buying Cipla, Take Solutions and Ipca Laboratories.

    • Buy Ipca Labs, target Rs 800-810: Rahul Mohindar

      Rahul Mohindar of viratechindia.com recommends buying Ipca Labs for a target of Rs 800-810.

    • Buy CESC, Ipca Labs, Glenmark Pharma, Rel Comm: Rajat Bose

      Rajat Bose of rajatkbose.com advises buying Glenmark Pharma, Ipca Labs and CESC.

    • Bull's Eye: Sell Bharat Forge, JSW Steel, buy Voltas

      Jay Thakkar of Sharekhan advises buying Dr Reddy's Laboratories with a target of Rs 4390.

    • Bull's Eye: Sell UPL, Ceat, LIC Housing, buy Delta Corp

      Vishal Malkan of malkansview.com is of the view that one may sell UPL with a target of Rs 500.

    • Check Out: Super Six stocks for August 21

      Jay Thakkar of ShareKhan suggests selling Axis Bank with a target of Rs 490.

    • Like Divis Laboratories, Torrent Pharma: Anmol Ganjoo

      Anmol Ganjoo of JM Financial likes Divis Laboratories and Torrent Pharma from the pharma space.

    • Glenmark Pharma top pick, like Ipca Lab: Sudip Bandopadhyay

      Sudip Bandopadhyay of Destimoney Securities is of the view that Glenmark Pharma is the top pick and likes Ipca Labs and Indoco Remedies.

    • 6 stocks likely to see lot of action today

      Jay Thakkar of ShareKhan is of the view that one may buy Ipca Laboratories with a target of Rs 875.

    • Ipca Laboratories may move to Rs 800-805: Rahul Mohindar

      Rahul Mohindar of viratechindia.com is of the view that Ipca Laboratories may move to Rs 800-805.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347